To evaluate the mechanism underlying the tumor-suppressing activity of fucoidan, we examined the expressions of p16INK4a, Cdk4/6 and pRb by western blotting in HepG2 cells after treatment with fucoidan for 24 h. This evidence concerns the gene CDKN2A and neoplasm.